Lexeo Therapeutics, Inc. (LXEO) Stock Price & Analysis
Lexeo Therapeutics, Inc. (LXEO) rose 0.71% to USD 4.24 as of June 10, 2026 at 01:09 UTC, according to Nexqual real-time market data.
LXEO last closed at USD 4.21; the session ranged USD 4.09–4.4 on volume of 420,089 shares. Market capitalization is $332.93M, with a 52-week range of USD 3.6–10.99 (NGM). Source: Nexqual, June 10, 2026 at 01:09 UTC.
Key Statistics (as of June 10, 2026 at 01:09 UTC)
| Price | USD 4.24 |
|---|---|
| Change | ▲ 0.71% (up) |
| Previous Close | USD 4.21 |
| Open | USD 4.31 |
| Day Range | USD 4.09 – 4.4 |
| 52-Week Range | USD 3.6 – 10.99 |
| Volume | 420,089 shares |
| Market Cap | $332.93M |
| Exchange | NGM |
Technical Analysis (LXEO)
Nexqual's technical model rates LXEO "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 01:09 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 32.09 (neutral) |
| vs SMA50 | Below (USD 5.61) |
| MACD | -0.38 (negative) |
Analyst Ratings (LXEO)
Wall Street analysts rate LXEO "None" based on 10 analysts, with a mean price target of USD 20.6 (range USD 12–30), per Nexqual as of June 10, 2026 at 01:09 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 20.6 |
| High Target | USD 30 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 10 / 0 / 0 |
Earnings (LXEO)
| Next Earnings Date | 2026-05-11 |
|---|---|
| EPS Estimate | USD -0.28 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.25 vs est -0.3 ▲ beat |
| 2025-12-31 | USD -0.27 vs est -0.3 ▲ beat |
| 2025-09-30 | USD -0.33 vs est -0.46 ▲ beat |
| 2025-06-30 | USD -0.68 vs est -0.66 ▼ miss |
Source: Nexqual, June 10, 2026 at 01:09 UTC.
Financials & Fundamentals (LXEO)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -54.75% |
| Debt / Equity | 3.18 |
| Current Ratio | 14.16 |
| Total Cash | $193.04M |
| Total Debt | $7.37M |
| Free Cash Flow | $-67.34M |
Source: Nexqual, June 10, 2026 at 01:09 UTC.
Financial Health Score (LXEO)
Nexqual rates Lexeo Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 01:09 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $193M cash vs $7M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$98M |
| Efficiency | Critical — ROE -55%, ROA -32.5% |
Ownership (LXEO)
| Insider Ownership | +0.60% |
|---|---|
| Institutional Ownership | +115.54% |
| Shares Outstanding | 78.52M |
| Float | 47.51M |
| Short % of Float | +20.62% |
Source: Nexqual, June 10, 2026 at 01:09 UTC.
Leadership (LXEO)
Lexeo Therapeutics, Inc. is led by R. Nolan Townsend (age 44), CEO & Director, per Nexqual as of June 10, 2026 at 01:09 UTC.
| CEO & Director | R. Nolan Townsend (age 44) |
|---|---|
| CFO & Principal Accounting Officer | Louis Tamayo (age 48) |
| Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board | Ronald G. Crystal |
| Chief Operating Officer | Jose Manuel Otero (age 46) |
| Senior Vice President of Regulatory Affairs | Keith Wonnacott |
Major Backers & Investors (LXEO)
Notable institutional backers of Lexeo Therapeutics, Inc. include Paradigm Biocapital Advisors LP, Affinity Asset Advisors, Llc, RA Capital Management, L.P., according to Nexqual as of June 10, 2026 at 01:09 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Paradigm Biocapital Advisors LP | 7.88% |
| Affinity Asset Advisors, Llc | 6.43% |
| RA Capital Management, L.P. | 6.37% |
| Janus Henderson Group PLC | 6.34% |
| Vestal Point Capital, LP | 5.7% |
| Frazier Life Sciences Management, L.P. | 5.64% |
| Citadel | 4.88% |
| Orbimed Advisors LLC. | 4.59% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.79% |
| State Street | 7.53% |
Source: Nexqual, June 10, 2026 at 01:09 UTC.
From Lexeo Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States.
- The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy.
- In addition, it is developing LX1001, LX1020, and LX1021, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MLYS | Mineralys Therapeutics, Inc. | USD 24.18 | ▲ 2.07% |
| NGNE | Neurogene Inc. | USD 28.81 | ▲ 8.76% |
| APGE | Apogee Therapeutics, Inc. | USD 85 | ▼ 2.21% |
| KYTX | Kyverna Therapeutics, Inc. | USD 7.85 | ▲ 5.09% |
| PEPG | PepGen Inc. | USD 1.38 | ▼ 2.13% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 01:09 UTC. This page is informational and not investment advice.